Annovis Bio

Q2 FY2026 EarningsQ2 FY26 results were mixed relative to consensus: GAAP EPS loss of $0.40 beat the mean estimate of -$0.45, while EBIT loss of $14.38M was narrower than the expected $18.32M loss. Clinical progress remains the primary catalyst, with the pivotal Phase 3 Alzheimer’s trial fully enrolled (850 patients) and top-line data anticipated in Q1 2027. However, the balance sheet remains lean with $18.7M in cash, suggesting a potential capital requirement before the 2027 readouts.